Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer

Advanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was...

Full description

Bibliographic Details
Main Authors: Nair Lopes, Mariana Brütt Pacheco, Diana Soares-Fernandes, Margareta P. Correia, Vânia Camilo, Rui Henrique, Carmen Jerónimo
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Biomedicines
Subjects:
hydralazine
enzalutamide
castration-resistant prostate cancer
epigenetics
Online Access:https://www.mdpi.com/2227-9059/9/8/976

Similar Items

Similar Items